These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37007556)

  • 1. Neoadjuvant therapy with
    Zhu J; Min N; Chen Y; Li X
    Ann Transl Med; 2023 Mar; 11(5):200. PubMed ID: 37007556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
    Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer.
    Gupta A; Gogia A; Deo S; Sharma DN; Mathur S; Sagiraju HKR
    Cancer Treat Res Commun; 2023; 36():100741. PubMed ID: 37453371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Value of Neoadjuvant Anthracycline-Based Regimens for HER2-Positive Breast Cancer: A Systematic Review and Meta-analysis Including 1366 Patients.
    Ding Y; Ding K; He X; Mo W; Liang C; Gong L; Huang Y; Ding X
    Clin Med Insights Oncol; 2023; 17():11795549231195293. PubMed ID: 37744425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis.
    Wu YT; Xu Z; Zhang K; Wu JS; Li X; Arshad B; Li YC; Wang ZL; Li HY; Wu KN; Kong LQ
    Ther Clin Risk Manag; 2018; 14():1789-1797. PubMed ID: 30310287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis.
    Villacampa G; Matikas A; Oliveira M; Prat A; Pascual T; Papakonstantinou A
    Eur J Cancer; 2023 Sep; 190():112885. PubMed ID: 37142539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
    van der Voort A; van Ramshorst MS; van Werkhoven ED; Mandjes IA; Kemper I; Vulink AJ; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS
    JAMA Oncol; 2021 Jul; 7(7):978-984. PubMed ID: 34014249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
    He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
    Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials.
    Wu YT; Xu Z; Arshad B; Wu JS; Zhang K; Wu H; Li X; Li H; Li YC; Wang ZL; Wu KN; Kong LQ
    J Cancer; 2018; 9(17):3168-3176. PubMed ID: 30210640
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role and efficacy of capecitabine in the anthracycline-free regimen in breast cancer patients: a systematic review and meta-analysis.
    Wang S; Deng L; Chen J; Li Y; Zhong Y; Wang Y; Cao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17671-17682. PubMed ID: 37891407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial.
    Conte B; Montemurro F; Levaggi A; Blondeaux E; Molinelli C; Cardinali B; Poggio F; Buzzatti G; Bighin C; Lambertini M; Del Mastro L
    Tumori; 2023 Feb; 109(1):71-78. PubMed ID: 34989265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
    Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
    Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012).
    Chen H; Maimaitiaili A; Liu Z; Ling R; Zhao Y; Yang H; Liu Y; Liu K; Zhang J; Mao D; Yu Z; Liu Y; Fu P; Wang J; Jiang H; Zhao Z; Tian X; Cao Z; Wu K; Song A; Jin F; He J; Fan Z; Zhang H
    Ther Adv Med Oncol; 2023; 15():17588359231156146. PubMed ID: 36891484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study.
    Wang H; Li Y; Qi Y; Zhao E; Kong X; Yang C; Yang Q; Zhang C; Liu Y; Song Z
    Front Oncol; 2022; 12():909426. PubMed ID: 35875123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
    Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
    Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.